Mitochondrial proteomics as a selective tool for unraveling Parkinson’s disease pathogenesis

  title={Mitochondrial proteomics as a selective tool for unraveling Parkinson’s disease pathogenesis},
  author={Ilse S. Pienaar and David T Dexter and Pierre R. Burkhard},
  journal={Expert Review of Proteomics},
  pages={205 - 226}
Parkinson’s disease (PD) is a neurodegenerative disease characterized by the large-scale loss of dopaminergic neurons in the substantia nigra and the formation of protein aggregates that accumulate in the cytoplasm of the remaining dopaminergic neurons. Most cases arise sporadically, while the precise cause remains obscure. This lack of understanding as to the etiology of PD continues to serve as a major barrier for delivering effective therapeutics. Mitochondria are potent integrators and… 
Proteomics in Human Parkinson’s Disease: Present Scenario and Future Directions
The present review summarizes the major advances in the field of PD research in humans utilizing proteomic techniques and potential samples for proteomic analysis and limitations associated with the analyses of different types of samples have also been discussed.
Mitochondrial proteomics—a tool for the study of metabolic disorders
This review describes several quantitative studies of proteins from mitochondria isolated by centrifugation, separated by various methods, and analyzed by advanced mass spectrometry, illustrating the methods by showing that multiple pathways and networks are affected in cells from patients carrying gene variations affecting a mitochondrial protein.
Unraveling the Neuroprotective Effect of Tinospora Cordifolia in Parkinsonian Mouse Model Through Proteomics Approach.
BackgroundStress-induced dopaminergic (DAergic) neuronal death in the midbrain region is the primary cause of Parkinson’s disease (PD). Approximately 2% of the global population aged above 65 years
Unraveling the Neuroprotective Effect of Tinospora cordifolia in a Parkinsonian Mouse Model through the Proteomics Approach.
This study demonstrates that Tc can exert therapeutic effects by regulating multiple pathways, resulting in neuroprotection, and provides novel insights into the PD progression as well as new therapeutic targets.
Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins
The extensive efforts to rapidly obtain differentially expressed proteomes and unravel the redox proteomic status in mitochondria have yielded clinical insights into the neuropathological mechanisms of disease, identification of disease early stage and evaluation of disease progression.
The role of α-synuclein in neurodegeneration — An update
Investigation in the early aggregation pathway, aberrant cellular effects, or secretion of α-synuclein might be targets for neuroprotection and disease-modifying therapy, and emerging evidence suggests that prionlike induction and seeding of β-pleated aggregation could lead to the spread of the pathology and disease progression.
Synaptic Protein Alterations in Parkinson’s Disease
Current understanding concerning the proteins involved in structural and functional changes that affect synaptic contact-points in PD are reviewed and the need for developing therapeutics aimed at deregulated protein synthesis and degradation pathways operating at axonal and dendritic synapses for preserving “normal” circuitry and function is emphasized.
Exploiting the potential of molecular profiling in Parkinson’s disease: current practice and future probabilities
The recent literature is critically evaluated to identify the key roadblocks and realistic opportunities facing researchers interested in utilizing molecular profiling in the clinic to improve the diagnosis and treatment of PD.
Parkinson's syndrome and Parkinson's disease in mitochondrial disorders
  • J. Finsterer
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2011
In the majority of cases, mitochondrial disorders are multisystem conditions that most frequently affect the skeletal muscle, followed by the central nervous system. One of the clinical
Mitochondrial dysfunction in Parkinson’s disease
The review highlights mitochondrial structural and functional abnormalities in Parkinson’s disease and experimental animal models of this pathology. Special attention is paid to the inactivation of


Neuroproteomics as a promising tool in Parkinson’s disease research
It is hoped that the application of neuroproteomics will lead towards a presymptomatic diagnosis of PD, and the identification of risk factors and new therapeutic targets at which pharmacological intervention can be aimed.
A proteomic approach in the study of an animal model of Parkinson's disease.
Applied proteomics: mitochondrial proteins and effect on function.
For any proteomics approach prefractionation of complex protein mixtures is essential to facilitate the identification of low-abundance proteins because the dynamic range of protein abundance within cells has been estimated to be as high as 10(7).
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Removal of Drosophila PINK1 homologue function results in male sterility, apoptotic muscle degeneration, defects in mitochondrial morphology and increased sensitivity to multiple stresses including oxidative stress, which underscores the importance of mitochondrial dysfunction as a central mechanism of Parkinson's disease pathogenesis.
Mitochondrial dysfunction in Parkinson's disease.
A novel model of PD is developed in which chronic, systemic infusion of rotenone, a complex-I inhibitor, selectively kills dopaminergic nerve terminals and causes retrograde degeneration of substantia nigra neurons over a period of months, which should enhance the understanding of neurodegeneration in PD.